This content supports the SDG Goal 3 by highlighting that management of chronic hepatitis B requires careful consideration of treatment indications given the requirement for long-term therapy in most patients. Options include nucleo(s)tide analogs (NA) and pegylated interferon alfa (PEG-IFN), both with their own advantages and limitations.